Navigation Links
Eisai Joins Groundbreaking Tuberculosis Drug Accelerator Partnership to Discover New Tuberculosis Drugs
Date:11/25/2013

TOKYO, Nov. 25, 2013 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has become a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, a groundbreaking initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB).

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

Jointly launched in June 2012 through a collaborative agreement among seven pharmaceutical companies1 and six research institutions2 with support from the Bill & Melinda Gates Foundation, the TBDA partnership targets the discovery of new TB drugs by working together on early-stage research. The long-term goal of the partnership is to create a new TB drug combination that has the potential to cure patients in only one month, compared to the six months of treatment required by existing drugs. Based on the partnership, the participating pharmaceutical companies will open up targeted sections of their compound libraries and share data with other participating pharmaceutical companies and research institutions. As a TBDA member, Eisai will provide selected portions of its chemical library for screening against TB as well as share identified and confirmed hits with other TBDA partners. Eisai will also work cooperatively with other partners to facilitate the development of new therapies for TB.

TB is a contagious disease caused by a bacterial infection that affects the lungs and other organs.  Although it is a curable and preventable disease, it is the second leading infectious cause of death worldwide, having resulted in the deaths of 1.4 million people in 2011 alone. One of the main reasons for the high mortality is that first-line therapies for TB are antiquated and inadequate, with all existing drugs being at least 50 years old and requiring at least six months to cure the disease. Furthermore, the length of the existing TB treatments means that a considerable number of patients drop out before completion, which in turn can lead to further transmission, emergence of drug resistance, and death. By discovering a new TB drug combination with the potential to cure patients in one month, the TBDA will contribute to shortening the length of treatment as well as decreasing treatment default rates.

Eisai is committed to improving the health and welfare of people in developing and emerging countries and considers its contributions to the economic development and expansion of the middle-income class through these endeavors as a form of long-term investment for future market growth. To achieve this, Eisai remains actively committed to addressing issues in global health to further increase the benefits provided to patients and their families worldwide.

1 AbbVie, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, Sanofi

2 Infectious Disease Research Institute, National Institute of Allergy and Infectious Diseases, Rutgers University, Texas A&M University, University of Dundee, Weill Cornell Medical College

Media Inquiries:  
Public Relations Department,  
Eisai Co., Ltd.  
+81-(0)3-3817-5120

 

 


'/>"/>
SOURCE Eisai Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
2. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
3. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
4. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
5. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
6. FDA Grants Orphan Drug Status To Eisais Lenvatinib
7. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
8. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
9. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
10. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
11. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... COLOGNE, Germany , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to ... http://photos.prnewswire.com/prnh/20160503/362920    Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... ACME Markets, Delaware County ... County Councilman Dave White announced today the ... ACME pharmacies across Delaware County . ... naloxone has saved 26,463 lives nationwide over the past 20 years. ... were authorized to administer naloxone to overdose victims, 244 ...
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology:
(Date:5/5/2016)... Francisco, CA (PRWEB) , ... ... ... intensive lectures and hands-on exercises, the Wharton Seminars for Business Journalists ... a better understanding of key business and economic issues.  This one-day program ...
(Date:5/5/2016)... ... May 05, 2016 , ... Every ... the most heartfelt wishes of these children. The wishes provide hope and ... President and CEO of Make-A-Wish Mississippi, Brent Wilson said, “In 2016, the organization ...
(Date:5/5/2016)... ... ... A recent survey by the Midwest Business Group on Health ... use the free preventive care benefits available to them as part of the Affordable ... public and private employers, MBGH found that only 10% of large employers are aware ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade students ... , Director of Allergy and Asthma Clinical Research in the Division of Pulmonary, ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... presented a talk highlighting the organization’s successful Care Transitions program at ... The talk was titled “Minimizing Costs in the Post-Acute Environment Through Effective Transitions ...
Breaking Medicine News(10 mins):